阿布昔替尼片在中国上市了吗?

Abxitinib tablets are a highly selective JAK1 inhibitor developed by Pfizer of the United States. It is mainly used to treat moderate to severe atopic dermatitis (AD). The drug has been marketed in many countries, including China, and has been included in the national medical insurance directory. This article will introduce in detail the marketing status, usage and dosage, and medical insurance information of Abxitinib Tablets in China to help patients and medical practitioners better understand this drug.

Are Abxitinib tablets available in China?

It has been officially launched in China, providing a new treatment option for domestic patients. The drug was developed by Pfizer of the United States. Since September 2021, it has been approved for marketing in many countries including the United Kingdom, Japan, and the European Union. On January 14, 2022, the U.S. Food and Drug Administration (FDA) also approved its marketing application in the United States.

Launch time and background

The launch time of Abxitinib tablets in China follows the global pace, bringing good news to domestic patients with atopic dermatitis.

Purchase Channels and Precautions

Patients can purchase Abxitinib tablets through hospitals or regular pharmacies. Since there are generic drugs on the market, patients should pay attention to the authenticity of the drugs when purchasing, check the production date, and avoid buying fake or inferior drugs. If there is a shortage of drugs, they can be purchased through regular medical service institutions.

The launch of Abxitinib tablets in China has filled the gap in related treatment fields and provided patients with more treatment options.

Usage and dosage of Abxitinib tablets

The usage and dosage of Absitinib tablets must be strictly followed by the doctor's instructions to reduce the occurrence of adverse reactions. This medicine is a film-coated tablet that should be swallowed whole and not crushed or chewed.

Recommended dose

The recommended dose of Abxitinib tablets is 100 mg, once daily. If a patient does not respond adequately to a dose of 100 mg, consider increasing the dose to 200 mg once daily. For patients under the age of 65 who need rapid relief of symptoms, treatment can be initiated with 200 mg once daily and adjusted to a maintenance dose of 100 mg after 12 weeks.

Dose adjustment for special groups

For patients with renal impairment, the dose needs to be reduced for patients with moderate impairment, and it is not recommended for patients with severe impairment. In patients with hepatic impairment, no dose adjustment is required in patients with mild or moderate impairment, but use should be avoided in patients with severe impairment. The recommended dose for patients with CYP2C19 slow metabolizers is 50 mg once daily, which can be increased to 100 mg if necessary.

The usage and dosage of Abxitinib tablets need to be adjusted according to the specific conditions of the patient, and it is recommended to be used under the guidance of a doctor.

Has Abxitinib Tablets been included in the national medical insurance?

Abxitinib Tablets has been successfully included in China’s national medical insurance catalog, greatly reducing the financial burden on patients. This move makes this innovative medicine affordable to more patients.

Medical insurance coverage

After Abxitinib tablets are included in the medical insurance, patients can reimburse part of the cost through the medical insurance. Specific reimbursement ratios and conditions may vary by region, and patients are advised to consult their local medical insurance department or hospital pharmacy for detailed information.

Significance to patients

After being included in medical insurance, the accessibility of Abxitinib tablets has been significantly improved, especially for patients with chronic kidney disease who require long-term medication. It not only reduces the cost of treatment, but also provides patients with more stable medication protection.

The inclusion of Abxitinib tablets in the national medical insurance is an important measure, which reflects the country’s care and support for patients with atopic dermatitis.